# Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

> **NCT05008224** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 146 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Doxorubicin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine
- **DRUG:** Bleomycin
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Procarbazine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05008224
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-07
- **Primary completion:** 2023-10-11
- **Final completion:** 2024-05-26
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05008224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05008224, "Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05008224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*